Amedisys Inc (NASDAQ:AMED) had its target price boosted by Robert W. Baird from $50.00 to $60.00 in a research note published on Friday morning. They currently have a neutral rating on the health services provider’s stock.
AMED has been the topic of several other research reports. Mizuho upgraded shares of Amedisys from a neutral rating to a buy rating and boosted their price target for the company from $55.00 to $65.00 in a research report on Thursday, November 2nd. Benchmark Co. upgraded shares of Amedisys from a hold rating to a buy rating and set a $56.00 price target on the stock in a research report on Thursday, November 2nd. BidaskClub upgraded shares of Amedisys from a sell rating to a hold rating in a research report on Friday, August 11th. Jefferies Group LLC reiterated a buy rating and set a $60.00 price target on shares of Amedisys in a research report on Thursday, October 12th. Finally, SunTrust Banks, Inc. reiterated a buy rating and set a $60.00 price target on shares of Amedisys in a research report on Monday, October 9th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $61.00.
Amedisys (AMED) traded down $0.14 during mid-day trading on Friday, hitting $56.25. 310,900 shares of the company’s stock were exchanged, compared to its average volume of 485,523. Amedisys has a 12-month low of $38.00 and a 12-month high of $65.91. The stock has a market capitalization of $1,908.96, a PE ratio of 26.91, a price-to-earnings-growth ratio of 1.37 and a beta of 0.68. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.33 and a quick ratio of 1.21.
Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, November 7th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.02. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The firm had revenue of $380.20 million for the quarter, compared to analysts’ expectations of $384.59 million. During the same quarter in the previous year, the company earned $0.36 earnings per share. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. research analysts expect that Amedisys will post 2.22 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/11/13/amedisys-inc-amed-price-target-increased-to-60-00-by-analysts-at-robert-w-baird.html.
A number of institutional investors and hedge funds have recently made changes to their positions in AMED. American Century Companies Inc. grew its holdings in Amedisys by 41.4% in the third quarter. American Century Companies Inc. now owns 1,671,680 shares of the health services provider’s stock worth $93,547,000 after purchasing an additional 489,220 shares during the period. Wells Fargo & Company MN grew its holdings in Amedisys by 29.7% in the third quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock worth $83,048,000 after purchasing an additional 339,825 shares during the period. Russell Investments Group Ltd. grew its holdings in Amedisys by 662.7% in the second quarter. Russell Investments Group Ltd. now owns 276,808 shares of the health services provider’s stock worth $17,387,000 after purchasing an additional 240,513 shares during the period. Balyasny Asset Management LLC purchased a new stake in Amedisys in the second quarter worth about $7,736,000. Finally, TimesSquare Capital Management LLC grew its holdings in Amedisys by 15.7% in the second quarter. TimesSquare Capital Management LLC now owns 731,670 shares of the health services provider’s stock worth $45,956,000 after purchasing an additional 99,380 shares during the period. Institutional investors and hedge funds own 96.36% of the company’s stock.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.